Skip to content
Home/Companies/Biotech/Nucleome Therapeutics
Nucleome Therapeutics

Nucleome Therapeutics

Biotech·UK·Active·7yr hold
Entry
2019
Hold
7yr
Status
Active

Who owns Nucleome Therapeutics?

Nucleome Therapeutics is currently owned by Oxford Science Enterprises through Oxford Science Enterprises Balance Sheet (2015 vintage), since 2019.

Hand-verified · updated 2026-07-16

Oxford Science Enterprises
Investor
Oxford Science Enterprises
Oxford Science Enterprises Balance Sheet · 2015 · Balance Sheet

Key facts

HQUK
SectorBiotech
StatusActive
Websitenucleome.com

More from Oxford Science Enterprises Balance Sheet

Other portfolio companies in the same fund.

YASA
YASA
Exited 2021
to
Allos
Allos
Active
AI/MLUK· 2026
Caudal Energy
Active
EnergyUK· 2026
Densix
Active
Deep TechUK· 2026
Marley Health
Marley Health
Active
HealthTechUK· 2026
Stateful Robotics
Stateful Robotics
Active
Deep TechUK· 2026

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Nucleome Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Nucleome Therapeutics?

5 strategic and 115financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Nucleome Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue